Skip to content
DataLookout
Menu

NCT06891300

Understanding and Treating Suicidal Ideation With Ketamine

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 16 words
    • Primary and study completion pushed from Oct 2026 to Mar 2027
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description expanded, about 3 words
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Sep 2026 to Oct 2026
    • Start date changed from estimate of Mar 2025 to Apr 8, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in white matter microstructure from pre-treatment to post-treatment, assessed via MRI.
Timeframe: Pre-treatment (up to -48 hours) to post-treatment (24+/-6 hours)

Secondary (2)

Change in extracellular free water from pre-treatment to post-treatment, assessed via MRI.
Change in neurite density index from pre-treatment to post-treatment, assessed via MRI.

Arms and interventions

KetamineExperimental

Participants will undergo a total of four IV ketamine infusions (0.5 mg/kg infused over 40 minutes), administered twice weekly for two weeks.

Drugs: ketamine hydrochloride

Sites

1 site in 1 country

  • Royal Ottawa Mental Health CentreOttawa, Ontario, Canada